Results 141 to 150 of about 811,174 (190)
Some of the next articles are maybe not open access.

The Clinical Landscape of HDAC Inhibitors

Medical Epigenetics, 2021
Arasu Ganesan
exaly  

The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors.

Clinical advances in hematology & oncology : H&O
Despite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some toxicities can be life-threatening, such as cardiotoxicity.
Fateeha, Furqan, Nirav N, Shah
openaire   +1 more source

BTK INHIBITORS

2023
MA BIN   +9 more
  +7 more sources

Therapeutics and DNA Methylation Inhibitors

Medical Epigenetics, 2021
Shyamala C Navada
exaly  

Recent Development of BTK-Based Dual Inhibitors in the Treatment of Cancers

European Journal of Medicinal Chemistry, 2022
Chi Meng, Jianqiang Qian, Yong Ling
exaly  

BTK inhibitors

2015
LIU JIAN   +5 more
openaire   +5 more sources

Pirtobrutinib Shows Evidence to Inaugurate a Third Generation of BTK Inhibitors

Lancet, The, 2021
Vincent Ribrag, Jean-Marie Michot
exaly  

Design, Synthesis, and Biological Evaluation of Pyrrolopyrimidine Derivatives as Novel Bruton's Tyrosine Kinase (BTK) Inhibitors

European Journal of Medicinal Chemistry, 2022
Xiaojian Wang   +2 more
exaly  

Home - About - Disclaimer - Privacy